| Literature DB >> 32665768 |
Mohammed Yosri1, Basma H Amin1, Nermine N Abed2, Amal S Elithy2, Sayed M Kareem1, Nagwa M Sidkey2.
Abstract
Gastric diseases are increasing with theEntities:
Mesh:
Substances:
Year: 2020 PMID: 32665768 PMCID: PMC7349621 DOI: 10.1155/2020/3591276
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Screening of the anti-Campylobacter jejuni activity of different plant extracts.
| Collected plants | Inhibited zone H2O extract | Inhibited zone methanol extract | Inhibited zone hexane extract |
|---|---|---|---|
|
| 8.03 ± 0.25 | 15.1 ± 0.00 | 12.0 ± 0.00 |
|
| 26.8 ± 0.51 | 18.0 ± 0.00 | 14.7 ± 0.00 |
|
| 11.2 ± 0.00 | 20.1 ± 0.00 | 11.5 ± 0.00 |
|
| 10.3 ± 0.00 | 15.1 ± 0.00 | 20.6 ± 0.00 |
|
| 31.7 ± 0.00 | 20.4 ± 0.00 | 18.6 ± 0.00 |
|
| 12.5 ± 0.00 | 15.2 ± 0.00 | 12.2 ± 0.00 |
|
| 7.7 ± 0.00 | 15.2 ± 0.00 | 17.3 ± 0.00 |
|
| 8.5 ± 0.00 | 10.6 ± 0.00 | 15.3 ± 0.00 |
|
| 16.4 ± 0.00 | 19.7 ± 0.00 | 30.2 ± 0.00 |
|
| 9.5 ± 0.00 | 9.3 ± 0.32 | 9.2 ± 0.00 |
|
| 8.4 ± 0.00 | 15.1 ± 0.00 | 8.0 ± 0.00 |
|
| 23.2 ± 0.00 | 8.2 ± 0.30 | 8.4 ± 0.00 |
|
| 10.2 ± 0.32 | 10.5 ± 0.00 | 11.4 ± 0.20 |
|
| 28.2 ± 0.30 | 15.7 ± 0.00 | 23.1 ± 0.20 |
|
| 24.1 ± 0.00 | 39.1 ± 0.00 | 20.2 ± 0.00 |
|
| 10.5 ± 0.00 | 15.4 ± 0.00 | 15.4 ± 0.00 |
|
| 10.4 ± 0.00 | 10.1 ± 0.00 | 13.2 ± 0.00 |
|
| 20.0 ± 0.2 | 9.9 ± 0.00 | 9.5 ± 0.35 |
|
| 16.8 ± 0.00 | 19.2 ± 0.1 | 30.4 ± 0.00 |
|
| 17.5 ± 0.15 | 22.4 ± 0.00 | 23.4 ± 0.00 |
Comparative antibacterial activity of different solvents extraction to Rheum officinalis.
| Solvent | Inhibition zone of crude (mm) | Inhibition zone of solvent (mm) |
|---|---|---|
| Hexane | 20.2 ± 0.0 | 0.0 |
| Chloroform | 12.3 ± 0.1 | 0.0 |
| Ethyl acetate | 15.1 ± 0.14 | 7.0 ± 0.0 |
|
| 15.0 ± 0.0 | 0.0 |
| Benzene | 13.0 ± 0.0 | 0.0 |
| Toluene | 18.0 ± 0.0 | 0.0 |
| Methanol | 39.1 ± 0.0 | 0.0 |
| Fats | 9.0 ± 0.0 | 0.0 |
Fractionation pattern of antibacterial agents produced by Rheum officinalis, using column chromatography, and their effect against C. jejuni NCTC11168.
| Fraction no. | Inhibited zone (mm) |
|---|---|
| 1 | 0.00 |
| 2 | 0.00 |
| 3 | 35 ± 0.00 |
| 4 | 33.3 ± 0.05 |
| 5 | 36.4 ± 0.11 |
| 6 | 0.00 |
| 7 | 0.00 |
| 8 | 0.00 |
| 9 | 0.00 |
| 10 | 0.00 |
| 11 | 32.1 ± 0.00 |
| 12 | 32.2 ± 0.00 |
| 13 | 37.7 ± 0.00 |
| 14 | 38.2 ± 0.00 |
| 15 | 31.2 ± 0.00 |
| 16 | 0.00 |
| 17 | 0.00 |
| 18 | 0.00 |
| 19 | 42.3 ± 0.1 |
| 20 | 39.1 ± 0.00 |
| 21 | 39.1 ± 0.00 |
| 22 | 39.3 ± 0.00 |
| 23 | 39.46 ± 0.15 |
| 24 | 0.00 |
Figure 1Fractionation pattern of antibacterial agents produced by Rheum officinalis, using column chromatography, and their effect against C. jejuni NCTC11168.
Screening of minimal inhibitory concentration of different concentrations of Rheum officinalis against C. jejuni NCTC11168.
| Concentration ( | Inhibited zone (mm) |
|---|---|
| 500 | 42.5 ± 0.0 |
| 250 | 37.5 ± 0.0 |
| 125 | 28.6 ± 0.0 |
| 62.50 | 17.5 ± 0.0 |
| 31.25 | 11.0 ± 0.0 |
| 15.62 | 0 |
| 7.81 | 0 |
| 3.90 | 0 |
| 1.95 | 0 |
| 0.97 | 0 |
Figure 2GC-MS of the purified bioactive compound from Rheum officinalis against C. jejuni NCTC11168.
Figure 3IR spectrum of the purified bioactive compound from Rheum officinalis against C. jejuni NCTC11168.
Figure 4NMR spectrum of the purified bioactive compound from Rheum officinalis against C. jejuni NCTC11168.
Figure 5Expected formula of the purified compound from Rheum officinalis tested against C. jejuni NCTC11168 (8-benzyl-2-methyl-3-phenyl-3,7,8,9-tetrahydro-6-oxa-3,8-diaza-cyclopenta[A]naphthalene-1-carboxylic acid ethyl ester).
Figure 6Effect of the purified compound from Rheum officinalis on isolated human lymphocytes. (a) Control. (b) Treated.